問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Division of Hematology & Oncology

Division of Thoracic Medicine

Division of General Internal Medicine

China Medical University Hospital-Taipei (在職)

Division of Hematology & Oncology

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

更新時間：2026-07-07

白禮源Bai, Li-Yuan
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -4 個月

Recruiting Trial

101Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

白禮源

List

207Cases

2026-09-01 - 2029-03-31

Phase III

Not yet recruiting
A Phase 3, randomized, open-label study (MAPKeeper 301) comparing atebimetinib combined with a modified gemcitabine and nab-paclitaxel regimen versus the standard gemcitabine and nab-paclitaxel regimen for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.

  • Condition/Disease

    Metastatic pancreatic adenocarcinoma

  • Test Drug

    Atebimetinib

Participate Sites
4Sites

Not yet recruiting4Sites

2019-11-01 - 2024-05-13

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2019-12-01 - 2022-12-31

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2020-01-01 - 2024-12-25

Phase I/II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2020-04-01 - 2025-01-31

Phase I

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting2Sites

Terminated2Sites

2020-07-01 - 2027-07-31

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2020-08-17 - 2023-12-12

Phase I/II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-10-26 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2026-06-01 - 2032-12-31

Phase III

Not yet recruiting
A phase 3, randomized, multicenter, open-label trial comparing velzatinib (GSK6042981) with imatinib in participants with previously untreated metastatic and/or unresectable gastrointestinal stromal tumors (GIST).

  • Condition/Disease

    Previously untreated metastatic and/or unresectable gastrointestinal stromal tumors

  • Test Drug

    Imatinib tablets 100mg Imatinib tablets 400mg Velzatinib (GSK6042981) Tablets 100mg

Participate Sites
5Sites

Not yet recruiting1Sites

2018-12-06 - 2026-03-31

Phase II

Active
A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients with Advanced Neuroendocrine Tumors

  • Condition/Disease

    Neuroendocrine Tumors Pancreatic Neuroendocrine Tumor Gastro-enteropancreatic Neuroendocrine Tumor Lung Neuroendocrine Neoplasm Neuroendocrine Carcinoma

  • Test Drug

    CVM-1118 Capsules

Participate Sites
8Sites

Recruiting3Sites

Terminated4Sites

陳明晃
Taipei Veterans General Hospital

Division of Hematology & Oncology

白禮源
China Medical University Hospital-Taipei

未分科

1 2 3 4 5 21
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB